Premary clinical efficacy and safety evaluation of sublingual immunotherapy in atopic dermatitis using "Dermatophagoides Farnae Dropes" - a multi-centre, randomized, double-blind, placebo-controlled study.

Trial Profile

Premary clinical efficacy and safety evaluation of sublingual immunotherapy in atopic dermatitis using "Dermatophagoides Farnae Dropes" - a multi-centre, randomized, double-blind, placebo-controlled study.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Apr 2016

At a glance

  • Drugs House dust mite allergy immunotherapy (Primary)
  • Indications Atopic dermatitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 May 2012 Planned end date 30 Nov 2012 added as reported by Chinese Clinical Trial Register.
    • 21 May 2012 Trial status is not yet recruiting as reported by Chinese Clinical Trial Register.
    • 10 Nov 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top